Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283170015> ?p ?o ?g. }
- W4283170015 endingPage "020" @default.
- W4283170015 startingPage "001" @default.
- W4283170015 abstract "Introduction: Several meta-analyses have reported the survival benefits and safety issues of chemotherapy regimens for pancreatic cancer (PC). The aim was to perform an umbrella review to summarize the existing evidence from meta-analyses of randomized controlled trials (RCTs). Methods: EMBASE, PubMed, Cochrane database of systematic reviews, and Epistemonikos were searched from inception to October 31st, 2021.Methodological quality was assessed using the A Measurement Tool to Assess Systematic Reviews (AMSTAR-2). The quality of evidence was evaluated using GRADE criteria (Grading of Recommendations, Assessment, Development, and Evaluations). Results: A total of 2,732 records were identified with 24 articles corresponding to 168 meta-analyses in resected/metastatic PC. Two (8.3%) studies were found to be of high methodological quality. Eighty (47.6%) meta-analyses reported survival benefits of using combination chemotherapy, while 88 (52.4%) meta-analyses reported safety outcomes. 78 (46.42%; 36-efficacy, 42-safety outcomes) of the 168 meta-analyses were statistically significant (P ≤0.05). No meta-analyses were found to be of high-quality evidence. Twelve meta-analyses reporting the survival benefits of gemcitabine combinations were graded as moderate quality of evidence. Combination regimen FOLFIRINOX, gemcitabine nab-paclitaxel (gem/nab), and gemcitabine capecitabine (gem/cap) compared to gemcitabine monotherapy were found to improve overall survival (OS) and progression free survival (PFS) for both resected (OS: HR = 0.78 (0.69-0.89); PFS: HR=0.79 (0.66-0.94)) and advanced PC (OS: HR = 0.76 (0.68-0.85); PFS: HR = 0.68 (0.60 -0.78)). One meta-analysis comparing the gemcitabine combination regimens (with Nab/Paclitaxel or Capecitabine) versus monotherapy among metastatic PC patients was upgraded to high quality after a sensitivity analysis excluding small-sized studies (PFS; HR = 0.78 (95% CI, 0.69-0.88)). The remaining meta-analyses were either low or very low quality of evidence. Conclusion: Our review showed that the use of combination chemotherapy regimens demonstrated survival benefits over gemcitabine monotherapy, which were supported by moderate to high-quality evidence. Gemcitabine combined with taxanes particularly showed high benefits for overall survival but only a modest benefit for progression free survival for metastatic PC. SWOG-1505 study compared perioperative FOLFIRINOX vs gem/nab in patients with resectable PC but no differences in survival was found. To date, FOLFIRINOX and gem/nab have been compared in the perioperative setting but no phase III trials have performed direct head-to-head comparisons for FOLFIRINOX against gemcitabine-based combination treatments in the metastatic setting. In future, head-to-head clinical trials comparing safety and efficacy for FOLFIRINOX vs gemcitabine-based combinations regimens (specifically gem/nab and gem/cap) in the metastatic setting are required." @default.
- W4283170015 created "2022-06-21" @default.
- W4283170015 creator A5006336008 @default.
- W4283170015 creator A5010122390 @default.
- W4283170015 creator A5013349830 @default.
- W4283170015 creator A5030098151 @default.
- W4283170015 creator A5045670044 @default.
- W4283170015 creator A5048276466 @default.
- W4283170015 creator A5074117459 @default.
- W4283170015 date "2022-06-03" @default.
- W4283170015 modified "2023-10-05" @default.
- W4283170015 title "Survival benefits and safety of chemotherapy regimens for pancreatic cancer: An umbrella review of meta-analyses of randomized controlled trials" @default.
- W4283170015 cites W1941634770 @default.
- W4283170015 cites W1974922522 @default.
- W4283170015 cites W1984108427 @default.
- W4283170015 cites W1991412268 @default.
- W4283170015 cites W2019490988 @default.
- W4283170015 cites W2033795072 @default.
- W4283170015 cites W2043986491 @default.
- W4283170015 cites W2079418758 @default.
- W4283170015 cites W2090481758 @default.
- W4283170015 cites W2102411026 @default.
- W4283170015 cites W2108868101 @default.
- W4283170015 cites W2113566724 @default.
- W4283170015 cites W2122450633 @default.
- W4283170015 cites W2145534346 @default.
- W4283170015 cites W2147466732 @default.
- W4283170015 cites W2151253787 @default.
- W4283170015 cites W2156813910 @default.
- W4283170015 cites W2165480504 @default.
- W4283170015 cites W2171676198 @default.
- W4283170015 cites W2179306384 @default.
- W4283170015 cites W2514008771 @default.
- W4283170015 cites W2528445830 @default.
- W4283170015 cites W2602492172 @default.
- W4283170015 cites W2619204019 @default.
- W4283170015 cites W2756578555 @default.
- W4283170015 cites W2771411730 @default.
- W4283170015 cites W2791860635 @default.
- W4283170015 cites W2897529224 @default.
- W4283170015 cites W2903623792 @default.
- W4283170015 cites W2953173394 @default.
- W4283170015 cites W2969661191 @default.
- W4283170015 cites W2970684805 @default.
- W4283170015 cites W2972659261 @default.
- W4283170015 cites W2976387938 @default.
- W4283170015 cites W2977696925 @default.
- W4283170015 cites W2982037555 @default.
- W4283170015 cites W2985763963 @default.
- W4283170015 cites W3007914843 @default.
- W4283170015 cites W3037470754 @default.
- W4283170015 cites W3047136679 @default.
- W4283170015 cites W3047482470 @default.
- W4283170015 cites W3128646645 @default.
- W4283170015 cites W3130998577 @default.
- W4283170015 cites W3148962211 @default.
- W4283170015 cites W3153075376 @default.
- W4283170015 cites W3183427139 @default.
- W4283170015 cites W3197559541 @default.
- W4283170015 cites W4200155910 @default.
- W4283170015 cites W4206841660 @default.
- W4283170015 cites W9613121 @default.
- W4283170015 doi "https://doi.org/10.17352/apdt.000008" @default.
- W4283170015 hasPublicationYear "2022" @default.
- W4283170015 type Work @default.
- W4283170015 citedByCount "1" @default.
- W4283170015 countsByYear W42831700152022 @default.
- W4283170015 crossrefType "journal-article" @default.
- W4283170015 hasAuthorship W4283170015A5006336008 @default.
- W4283170015 hasAuthorship W4283170015A5010122390 @default.
- W4283170015 hasAuthorship W4283170015A5013349830 @default.
- W4283170015 hasAuthorship W4283170015A5030098151 @default.
- W4283170015 hasAuthorship W4283170015A5045670044 @default.
- W4283170015 hasAuthorship W4283170015A5048276466 @default.
- W4283170015 hasAuthorship W4283170015A5074117459 @default.
- W4283170015 hasBestOaLocation W42831700151 @default.
- W4283170015 hasConcept C121608353 @default.
- W4283170015 hasConcept C126322002 @default.
- W4283170015 hasConcept C143998085 @default.
- W4283170015 hasConcept C168563851 @default.
- W4283170015 hasConcept C17744445 @default.
- W4283170015 hasConcept C189708586 @default.
- W4283170015 hasConcept C199539241 @default.
- W4283170015 hasConcept C2776694085 @default.
- W4283170015 hasConcept C2777909004 @default.
- W4283170015 hasConcept C2779473830 @default.
- W4283170015 hasConcept C2780210213 @default.
- W4283170015 hasConcept C2780258809 @default.
- W4283170015 hasConcept C2781413609 @default.
- W4283170015 hasConcept C526805850 @default.
- W4283170015 hasConcept C71924100 @default.
- W4283170015 hasConcept C95190672 @default.
- W4283170015 hasConceptScore W4283170015C121608353 @default.
- W4283170015 hasConceptScore W4283170015C126322002 @default.
- W4283170015 hasConceptScore W4283170015C143998085 @default.
- W4283170015 hasConceptScore W4283170015C168563851 @default.
- W4283170015 hasConceptScore W4283170015C17744445 @default.
- W4283170015 hasConceptScore W4283170015C189708586 @default.